Zoetis (ZTS) has experienced a significant fall in the market, more substantial than the overall market decline. Yet, it remains a top value stock for long-term investment due to solid earnings reports for Q3 and Q4 2024, Q1, Q2, and Q3 2025. Persistent shareholder rights activism indicates continued engagement with company management. However, a shift with a deeper focus on biologics following their World Vaccine Congress update suggests an innovative strategy to boost revenue generation. Despite recent share price weakness and the setback from Librela, the long-term growth potential remains viable. Zoetis continues to align with Morgan Stanley's 2026 Healthcare Playbook despite an adjusted 2026 outlook affected by softer pet visits and regulatory scrutiny. Following Q3's disappointment and Librela's reduced demand, the company still beat Q4 earnings and revenue estimates. Executive rewards like cash-settled Phantom Stock Units suggest management's confidence in growth and recovery. Bank of America acknowledged the strong Q4 and fiscal 2026 outlook.BofA Securities and Argus Research maintain their ratings while advising a $140 target price. Despite a 24% one-year share price pullback, Zoetis remains an attractive investment opportunity due to projected 2026 recovery and robust profit margins despite a premium valuation.
Zoetis ZTS News Analytics from Tue, 09 Sep 2025 07:00:00 GMT to Sat, 11 Apr 2026 09:23:00 GMT - Rating 5 - Innovation 5 - Information 7 - Rumor -5
